Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Treasury Shares (2022 - 2025)

Indivior Pharmaceuticals has reported Treasury Shares over the past 4 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.1 million for Q4 2025, up 104.05% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (up 104.05% YoY), and the annual figure for FY2025 was $2.1 million, up 104.05%.
  • Treasury Shares for Q4 2025 was $2.1 million at Indivior Pharmaceuticals, down from $2.5 million in the prior quarter.
  • Over the last five years, Treasury Shares for INDV hit a ceiling of $5.9 million in Q4 2022 and a floor of $1.0 million in Q4 2024.
  • Median Treasury Shares over the past 4 years was $2.5 million (2025), compared with a mean of $3.2 million.
  • Biggest five-year swings in Treasury Shares: crashed 80.39% in 2023 and later soared 104.05% in 2025.
  • Indivior Pharmaceuticals' Treasury Shares stood at $5.9 million in 2022, then crashed by 80.39% to $1.2 million in 2023, then dropped by 11.23% to $1.0 million in 2024, then surged by 104.05% to $2.1 million in 2025.
  • The last three reported values for Treasury Shares were $2.1 million (Q4 2025), $2.5 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.